vTv Therapeutics Inc (NASDAQ: VTVT) — Healthcare · Share Price, Chart & Market Data
About: vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $32.76 (-6.00%)
VTVTvTv Therapeutics Inc
Loading watchlist status…
Trade VTVT now
vTv Therapeutics Inc share price
VTVT price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:07 am GMT+0
VTVT price performance
-14.909%
5D
-14.931%
1M
-17.273%
YTD
41.39%
1Y
VTVT price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:07 am GMT+0
VTVT details
VTVT Market Signals